PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsChoriogonadotropin alfa
Ovidrel, Ovitrelle(choriogonadotropin alfa)
Ovidrel, Ovitrelle (choriogonadotropin alfa) is a protein pharmaceutical. Choriogonadotropin alfa was first approved as Ovidrel on 2000-09-20. It is used to treat cryptorchidism, female infertility, and hypogonadism in the USA. It has been approved in Europe to treat anovulation, assisted reproductive techniques, and female infertility.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
hereditary congenital and neonatal diseases and abnormalitiesD009358
endocrine system diseasesD004700
therapeuticsD013812
investigative techniquesD008919
reproductive and urinary physiological phenomenaD012101
Trade Name
FDA
EMA
Ovidrel (discontinued: Ovidrel)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Choriogonadotropin alfa
Tradename
Proper name
Company
Number
Date
Products
Ovidrelchoriogonadotropin alfaEMD SeronoN-21149 RX2003-07-14
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ovidrelBiologic Licensing Application2023-12-26
pregnylBiologic Licensing Application2024-12-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
female infertilityEFO_0008560D007247N97
hypogonadism—D007006E23.0
cryptorchidismEFO_0004562D003456Q53.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03G: Gonadotropins and other ovulation stimulants
— G03GA: Gonadotropins
— G03GA08: Choriogonadotropin alfa
HCPCS
No data
Clinical
Clinical Trials
357 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246EFO_0000545——22115
HypogonadismD007006—E23.0———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Primary ovarian insufficiencyD016649EFO_0004266E28.3—1———1
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovulation inductionD010062——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameChoriogonadotropin alfa
INNchoriogonadotropin alfa
Description
Choriogonadotropin beta chain [Precursor]; Glycoprotein hormones alpha chain [Precursor];
Classification
Protein
Drug classtricyclic compounds; atropine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI4986
ChEMBL IDCHEMBL1201464
ChEBI ID—
PubChem CID—
DrugBankDB09126
UNII ID20ED16GHEB (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,824 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,883 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use